Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 13, 2024

SELL
$0.84 - $1.22 $706 - $1,026
-841 Reduced 22.43%
2,909 $3,000
Q3 2023

Nov 14, 2023

SELL
$0.82 - $1.42 $1,560 - $2,702
-1,903 Reduced 33.66%
3,750 $3,000
Q2 2023

Aug 21, 2023

BUY
$1.09 - $9.93 $6,161 - $56,134
5,653 New
5,653 $6,000
Q2 2022

Aug 15, 2022

SELL
$2.21 - $5.56 $15,131 - $38,069
-6,847 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$5.07 - $13.68 $9,491 - $25,608
-1,872 Reduced 21.47%
6,847 $35,000
Q4 2021

Feb 15, 2022

BUY
$11.91 - $17.0 $48,783 - $69,632
4,096 Added 88.6%
8,719 $112,000
Q3 2021

Nov 15, 2021

SELL
$13.21 - $20.91 $74,438 - $117,827
-5,635 Reduced 54.93%
4,623 $69,000
Q2 2021

Aug 16, 2021

BUY
$15.08 - $20.3 $154,690 - $208,237
10,258 New
10,258 $159,000

Others Institutions Holding RAIN

About Rain Therapeutics Inc.


  • Ticker RAIN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 18,837,400
  • Description
  • Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in...
More about RAIN
Track This Portfolio

Track California State Teachers Retirement System Portfolio

Follow California State Teachers Retirement System and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of California State Teachers Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on California State Teachers Retirement System with notifications on news.